• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season.

作者信息

Litman Ethan A, Hsieh Tina Yi Jin, Modest Anna M, Clarke Kathleen, Dzinoreva Melissa, Perrinez Valerie, Apraku Bondzie Esther, Gallup Lydia, Schonberg Eleanor, Rowe Marjorie, Locke K'ara, Oginni Oluwaseyi, Jones Robert, Zera Chloe A, Collier Ai-Ris Y

机构信息

Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Netw Open. 2025 Feb 3;8(2):e2460729. doi: 10.1001/jamanetworkopen.2024.60729.

DOI:10.1001/jamanetworkopen.2024.60729
PMID:39969883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11840643/
Abstract
摘要

相似文献

1
Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season.呼吸道合胞病毒流行季期间孕产妇呼吸道合胞病毒前融合蛋白疫苗及婴儿nirsevimab疫苗的接种情况
JAMA Netw Open. 2025 Feb 3;8(2):e2460729. doi: 10.1001/jamanetworkopen.2024.60729.
2
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates.呼吸道合胞病毒疫苗及尼塞韦单抗在孕妇及其新生儿中的接种情况
JAMA Netw Open. 2025 Feb 3;8(2):e2460735. doi: 10.1001/jamanetworkopen.2024.60735.
3
Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus.使用呼吸道合胞病毒融合前体蛋白（RSVpreF）对迪拜的私人保险婴儿进行母体疫苗接种以预防呼吸道合胞病毒的预算影响。
Hum Vaccin Immunother. 2025 Dec;21(1):2523106. doi: 10.1080/21645515.2025.2523106. Epub 2025 Jul 2.
4
Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.荷兰保护婴儿免受呼吸道合胞病毒感染的免疫策略的成本效益
Hum Vaccin Immunother. 2025 Dec;21(1):2521912. doi: 10.1080/21645515.2025.2521912. Epub 2025 Jun 25.
5
Maternal RSVpreF Vaccine: A Novel Agent for Respiratory Syncytial Virus Prevention in Infants.母体呼吸道合胞病毒前融合蛋白疫苗：预防婴儿呼吸道合胞病毒的新型制剂。
Ann Pharmacother. 2025 Aug;59(8):758-766. doi: 10.1177/10600280241302775. Epub 2024 Dec 30.
6
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.Nirsevimab预防婴儿呼吸道合胞病毒下呼吸道感染住院治疗的180天疗效（HARMONIE）：一项随机对照3b期试验
Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6.
7
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.加拿大婴儿呼吸道合胞病毒疾病预防用 RSVpreF 疫苗和 nirsevimab 的成本效益分析。
Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.
8
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.在接受尼塞韦单抗突破性感染后呼吸道合胞病毒的基因和表型特征：一项大型、多中心、观察性、真实世界研究。
Lancet Infect Dis. 2025 Mar;25(3):301-311. doi: 10.1016/S1473-3099(24)00570-X. Epub 2024 Oct 14.
9
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
10
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.尼赛珠单抗预防婴儿呼吸道合胞病毒住院治疗。
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.

引用本文的文献

1
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.长效单克隆抗体预防呼吸道合胞病毒疾病应用的系统评价与专家共识：ARMADA（推进呼吸道合胞病毒管理与疾病认知）工作组
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
2
Respiratory Syncytial Virus Vaccination Acceptance: The Importance of Asking "Why?".呼吸道合胞病毒疫苗接种的接受度：询问“为什么？”的重要性。
J Pediatr Clin Pract. 2025 Jul 7;17:200163. doi: 10.1016/j.jpedcp.2025.200163. eCollection 2025 Sep.

本文引用的文献

1
Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes.无佐剂双联呼吸道合胞病毒疫苗接种与围产期结局。
JAMA Netw Open. 2024 Jul 1;7(7):e2419268. doi: 10.1001/jamanetworkopen.2024.19268.
2
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
3
Inequities in COVID-19 Vaccination Coverage Among Pregnant Persons, by Disaggregated Race and Ethnicity - Massachusetts, May 2021-October 2022.
按种族和民族细分的 COVID-19 疫苗接种覆盖差距-马萨诸塞州，2021 年 5 月至 2022 年 10 月。
MMWR Morb Mortal Wkly Rep. 2023 Sep 29;72(39):1052-1056. doi: 10.15585/mmwr.mm7239a2.
4
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《使用尼赛珠单抗预防婴幼儿呼吸道合胞病毒疾病：免疫实践咨询委员会的建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920-925. doi: 10.15585/mmwr.mm7234a4.